

**★ AAD 1: Psoriasis: Assessment of Psoriasis Disease Activity– National Quality Strategy Domain: Effective Clinical Care**

**DESCRIPTION:**

Percentage of patients with plaque psoriasis who have disease activity assessed by using one of the listed measures or validated instruments/ tools\* at least once during the measurement period.

\* Assessment and classification of disease activity using standardized descriptive measures or tools resulting in a numeric score or composite index: Scales and instruments are examples and cut-points can differ by scale. Standardized descriptive or numeric scales and/or composite indexes include: Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), Physician's Global Assessment (PGA), Dermatology Life Quality Index (DLQI).

**INSTRUCTIONS:**

This measure is to be reported a minimum of once per reporting period for all patients during the reporting period. It may be reported by clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding. This measure is to be reported for patients who come in during the reporting period and have their psoriasis (new or established) assessed during the encounter.

**Measure Reporting via Registry**

ICD-10-CM diagnosis codes, CPT codes or HCPCS codes and patient demographics are used to identify patients who are included in the measure's denominator. The listed numerator options are used to report the numerator of the measure.

The quality-data codes listed do not need to be submitted for registry-based submissions; however, these codes may be submitted for those registries that utilize claims data.

**DENOMINATOR:**

All patients with a diagnosis of plaque psoriasis

Denominator Criteria (Eligible Cases):

Patients who meet each of the following criteria are included in the population:

- Patient aged 18 years or older at the start of the measurement period.
- Patient had an outpatient face to face encounter
- Patient had diagnosis of psoriasis

CPT Codes for Identifying Eligible Face-to-Face Encounters: 99201, 99202, 99203, 99204, 99205, 99211, 99212, 99213, 99214, 99215

Diagnosis Codes for Identifying Patients with Psoriasis: 696.1, L40.0

**NUMERATOR:**

A psoriasis patient's disease activity is assessed and documented in the medical record using any of the listed measures or validated instruments/ tools at least once during the measurement period.

### Tools for Assessing Psoriasis Disease Activity:

Any one of the following tools may be used to assess the patient's disease activity

1. Psoriasis Area and Severity Index (PASI)
2. Body Surface Area (BSA) Value
3. Body Surface Area (BSA) Range
4. Physician's Global Assessment (PGA) 5 point scale
5. Physician's Global Assessment (PGA) 6 point scale
6. Physician's Global Assessment (PGA) 7 point scale
7. Dermatology Life Quality Index (DLQI)

### Exclusions:

None

### Potential Benchmarks:

Year 1 of reporting:  $\geq 60\%$

Year 2 of reporting:  $\geq 70\%$

Subsequent years:  $\geq 80\%$

### **RATIONALE:**

Assessment of psoriasis disease activity is critical for guiding treatment choice, determining treatment response, and, thus, measuring quality of care. Psoriasis activity or severity may be measured by any of several measures including body surface area (BSA) affected by psoriasis and other tools for physician-reported (e.g. Physician Global Assessment (PGA), Psoriasis Area and Severity Index (PASI), etc.) or patient-reported Dermatology Life Quality Index (DLQI, etc.) disease activity. Such measures are used regularly in clinical trials to determine the efficacy of psoriasis therapies; however, use of such measures in clinical practice is inconsistent. This measure evaluates the percentage of patients with psoriasis whose disease activity has been evaluated and documented at least once yearly.

### **CLINICAL RECOMMENDATION STATEMENTS:**

This measure will assess disease activity in patients with plaque psoriasis which is important in measuring quality of life through guiding treatment choice and determining treatment response.

### **COPYRIGHT:**

©American Academy of Dermatology/Association. All rights reserved.

The American Academy of Dermatology and the American Academy of Dermatology Association (collectively AAD/A) own all right, title, and interest in this quality measure. This quality measure is provided solely for the benefit of AAD/A and its members for the purposes specified herein and for other AAD/A purposes. It may not be used by other parties except with prior written approval of the AAD/A.